NSD2 is also highly expressed in metastatic prostate cancer, where its repression can inhibit metastasis [54], so that NSD2 has been proposed as a key driver of the tumor, and therefore, as a critical therapeutic target for this disease. The gene discussed is NSD2; the disease is neoplasm.